[Aquired immune hemolytic anemias].

Area of Science:

• Hematology
• Immunology
• Internal Medicine

Context:

• Acquired immune hemolytic anemias (AIHA) represent a group of disorders characterized by autoantibody production against red blood cells.
• These anemias have diverse etiologies, including autoimmune processes, infections, and drug reactions.
• Understanding the classification and underlying mechanisms is crucial for effective management.

Purpose:

• To classify acquired immune hemolytic anemias based on autoantibody characteristics and clinical presentation.
• To outline the primary therapeutic strategies for different subtypes of AIHA.
• To highlight the varying incidence and specific etiological factors for each type.

Summary:

• AIHA includes warm autoantibody type (reacting at 37°C, often IgG), cold agglutinin disease, paroxysmal cold hemoglobinuria, and drug-induced immune hemolytic anemia.
• Idiopathic AIHA accounts for 50% of cases, while others are associated with underlying diseases.
• Corticosteroids are the first-line treatment for warm AIHA, often requiring additional immunosuppressants; cold agglutinin disease and drug-induced forms have distinct management approaches.

Impact:

• Provides a clear classification of acquired immune hemolytic anemias for clinicians and researchers.
• Emphasizes the importance of identifying specific autoantibody types for targeted therapy.
• Underscores the need for further research into the etiology of idiopathic AIHA and the incidence of alloimmune hemolytic anemias.